Contact Us
Drug Search Results
More Filters [+]

Lucerastat

Alternative Names: lucerastat
Latest Update: 2024-11-15
Latest Update Note: Clinical Trial Update

Product Description

Idorsia is developing Lucerastat as a treatment for Fabry disease. (Sourced from: https://www.idorsia.com/media/news-details?newsId=2608540)

Mechanisms of Action: GCS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lucerastat

Countries in Clinic: Australia, Austria, Belgium, Canada, France, Germany, Japan, Norway, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Fabry Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ID-069A302

P3

Unknown Status

Fabry Disease

2027-11-23

ID-069A302

P3

Active, not recruiting

Fabry Disease

2025-10-29

2018-002210-12

P3

Unknown status

Fabry Disease

2025-09-18

jRCT2080224890

P3

Completed

Fabry Disease

2024-03-31

Recent News Events

Date

Type

Title

01/01/1993

PubMed

 Fabry Disease.

04/30/2024

PubMed

 A systematic literature review on the health-related quality of life and economic burden of Fabry disease.

02/19/2024

PubMed

 Baseline Characteristics of Fabry Disease "Amenable" Migalastat Patients in Argentinian Cohort.

07/25/2023

News Article

 Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value

07/20/2023

News Article

 Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million

07/20/2023

News Article

 Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

04/25/2023

News Article

 Idorsia announces financial results for the first quarter 2023 – QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions